{
    "clinical_study": {
        "@rank": "35212", 
        "arm_group": [
            {
                "arm_group_label": "A-101 25%", 
                "arm_group_type": "Active Comparator", 
                "description": "Low dose group"
            }, 
            {
                "arm_group_label": "A-101 32.5%", 
                "arm_group_type": "Active Comparator", 
                "description": "Mid Dose Group"
            }, 
            {
                "arm_group_label": "A-101 40%", 
                "arm_group_type": "Active Comparator", 
                "description": "High Dose Group"
            }, 
            {
                "arm_group_label": "A-101 Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo group"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluate the safety, tolerability of A-101 when applied to seborrheic keratosis lesions on\n      the back of subjects."
        }, 
        "brief_title": "Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Seborrheic Keratosis", 
        "condition_browse": {
            "mesh_term": [
                "Keratosis", 
                "Keratosis, Actinic", 
                "Keratosis, Seborrheic"
            ]
        }, 
        "detailed_description": {
            "textblock": "The main objective of this study is to evaluate the safety, effectiveness and tolerability\n      of three concentrations of A-101 25%, 32.5%, and 40%, when applied to individual seborrheic\n      keratosis target lesions on the back compared with a matching A-101 vehicle."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Is at least 18 years of age\n\n          2. Has a clinical diagnosis of stable clinically typical seborrheic keratosis\n\n          3. Has at least 4 appropriate seborrheic keratosis target lesions on the back\n\n          4. If subject is a women of childbearing potential, she must have a negative urine\n             pregnancy test and must agree to use an active form of birth control for the duration\n             of the study\n\n          5. Is non-pregnant and non-lactating\n\n          6. Is in good general health and free of any disease state or physical condition which,\n             in the investigator's opinion, might impair evaluation of any target lesion or which\n             exposes the subject to an unacceptable risk by study participation\n\n          7. Is willing and able to follow all study instructions and to attend all study visits\n\n          8. Is able to comprehend and willing to sign an Informed Consent Form (ICF).\n\n        Exclusion Criteria:\n\n          1. Has clinically atypical and/or rapidly growing seborrheic keratosis lesions\n\n          2. Has presence of multiple eruptive seborrheic keratosis lesions (Sign of\n             Lesser-Trelat)\u2003\n\n          3. Has used any of the following systemic therapies within the specified period prior to\n             Visit 1:\n\n               -  Retinoids; 180 days\n\n               -  Glucocortico-steroids; 28 days\n\n               -  Anti-metabolites (e.g., methotrexate); 28 days\n\n          4. Has used any of the following topical therapies on the treatment area within the\n             specified period prior to Visit 1:\n\n               -  Retinoids; 90 days\n\n               -  Liquid nitrogen, electrodessication, curettage, imiquimod, 5-flurouracil, or\n                  ingenol mebutate; 60 days\n\n               -  Glucocortico-steroids or antibiotics; 14 days\n\n               -  Moisturizers/emollients, sunscreens; 12 hours\n\n          5. Has had any LASER, light (e.g., intense pulsed light [IPL], photo-dynamic therapy\n             [PDT]) or other energy based therapy on the treatment area within 180 days prior to\n             Visit 1\n\n          6. Has a history of keloid formation or hypertrophic scarring\n\n          7. Has a current systemic malignancy\n\n          8. Has a history of, within the 180 days prior to Visit 1, or has a current cutaneous\n             malignancy  on the treatment area\n\n          9. Has a current pre-malignancy (e.g., actinic keratosis) on the treatment area\n\n         10. Has had body art (e.g., tattoos, piercing, sculpting, etc.) or any other invasive,\n             non-therapeutic procedure performed on the treatment area that, in the opinion of the\n             investigator, might put the subject at undue risk or interfere with the study conduct\n             or evaluations\n\n         11. Has excessive tan on the treatment area that, in the opinion of the investigator,\n             might put the subject at undue risk or interfere with the study conduct or\n             evaluations\n\n         12. Has experienced a sunburn on the treatment area within the previous 4 weeks\n\n         13. Has a history of sensitivity to any of the ingredients in the study medications\n\n         14. Has any current skin disease (e.g., psoriasis, atopic dermatitis,  eczema, sun\n             damage, etc.), or condition (e.g., sunburn, tattoos, excessive hair, open wounds on\n             the back) that, in the opinion of the investigator, might put the subject at undue\n             risk or interfere with the study conduct or evaluations\n\n         15. Has participated in an investigational drug trial in which administration of an\n             investigational study medication occurred within 30 days prior to Visit 1."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01986920", 
            "org_study_id": "A-101-SEBK-201"
        }, 
        "intervention": [
            {
                "arm_group_label": "A-101 25%", 
                "description": "Low Dose Concentration of A-101", 
                "intervention_name": "A-101 25%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "A-101 32.5%", 
                "description": "Mid Dose Concentration of A-101", 
                "intervention_name": "A-101 32.5%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "A-101 40%", 
                "description": "High Dose Concentration A-101", 
                "intervention_name": "A-101 40%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "A-101 Vehicle", 
                "description": "Placebo", 
                "intervention_name": "A-101 Vehicle", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "SK", 
        "lastchanged_date": "March 10, 2014", 
        "link": {
            "description": "Study Sponsor Website", 
            "url": "http://www.aclaristx.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Austin", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78759"
                }, 
                "name": "DermResearch, Inc."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double-Blind, Vehicle-Controlled, Within-Subject, Comparison Study of the Safety, Tolerability, And Effectiveness of A-101 Topical Solution in Subjects With Seborrheic Keratosis", 
        "overall_official": {
            "affiliation": "Dermresearch, Inc.", 
            "last_name": "Janet Dubois, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Physician's subjective assessment of the condition of the lesion", 
            "measure": "Physician Lesion Assessment Scale", 
            "safety_issue": "No", 
            "time_frame": "Day 78"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01986920"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Subjects assessment of the condition of their lesions", 
            "measure": "Subject's Self Assessment Scale", 
            "safety_issue": "No", 
            "time_frame": "Day 78"
        }, 
        "source": "Aclaris Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aclaris Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}